ReviewImmunotoxins in cancer therapy
Introduction
It has been estimated that — in the year 1999 — 1,228,000 people in the US will be diagnosed with invasive cancer and 564,800 people are expected to die of it [1]. Treatment of cancer classically consisted of surgery, radiation therapy and chemotherapy — the latter having had the sole task of treating widespread disease that usually afflicts the dying cancer patient. The success of chemotherapy requires the malignant cells to be sensitive by virtue of intracellular metabolic processes or growth rates that are different from those of normal cells.
Section snippets
A different modality for cancer treatment
Human cancer is becoming more definable by surface proteins displayed on the malignant cell surface. Targeting cells selectively via these surface proteins is inherently different from surgery, radiation and chemotherapy and is often considered a new modality for cancer therapy. Targeted therapy can be accomplished by using monoclonal antibodies (MAbs) alone or MAbs armed with radionuclides or toxins. The Food and Drugs Administration (FDA) recently approved the MAbs Rituximab and Herceptin,
Immunotoxins targeting hematologic tumors
Hematologic malignancies are easier to target than solid tumors for many reasons, including easy access of the immunotoxin to intravascular tumor cells and improved penetration of lymphomatous tumor cells without tight junctions. Moreover, fresh cells may be easily tested for immunotoxin binding and cytotoxic activity. Immunotoxins have also been developed for indirect treatment of malignancies by their killing of T cells that mediate graft-versus-host disease (GVHD) in the setting of
Solid tumors
The treatment of solid tumors with immunotoxins is challenging due to tight junctions between tumor cells, high interstitial pressure within tumors and heterogeneous blood supply [46]. As described below, to deal with these obstacles some immunotoxins are being administered locally to solid tumors. Nevertheless, some systemically administered immunotoxins have recently shown efficacy in patients with solid tumors.
Targeting tumors in the central nervous system
Since the transferrin receptor (TfR) is expressed on tumor and normal hepatic cells but not in normal brain, several trials have targeted anti-TfR immunotoxins to brain tumors. The conjugate 454A12–rRA — composed of an anti-TfR MAb, 454A12, and recombinant ricin A chain — was used for intraventricular therapy of patients with leptomeningeal cancer and cleared > 50% of the malignant cells from the cerebrospinal fluid (CSF) in half of the patients [54]. These same investigators have also targeted
Immunogenicity
Although durable partial and even complete responses have resulted from one cycle of immunotoxin therapy, immunogenicity is considered a major barrier to the clinical utility of chimeric toxins. Table 1 includes immunogenicity data from recent clinical trials, indicating that patients with solid tumors become immunized much more readily that those with hematologic tumors. Some hematologic tumors may be associated with less immunogenicity than others. None of 14 patients with chronic lymphocytic
Conclusions
Chimeric toxins have become a new modality for the treatment of cancer. Despite difficulties with immunogenicity, toxicity to normal tissues and limitations in tumor penetration, they are unique in their ability to rationally target tumor cells via cell surface receptors. The ability to kill a cell with only one or a few molecules of toxin in the cytoplasm permits successful targeting of cells displaying only a limited number of antigen molecules. Several immunotoxins can target cells mediating
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
References (97)
- et al.
Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain
J Immunol Methods
(1990) - et al.
Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains
J Immunol Methods
(1993) - et al.
Use of bacteriophage T7 polymerase to direct selective expression of cloned genes
J Mol Biol
(1986) - et al.
A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies
Anal Biochem
(1992) - et al.
Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells
Blood
(1997) - et al.
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2
Blood
(1998) - et al.
Production of recombinant DT(ct)GMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies
Protein Expr Purif
(1998) - et al.
Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma
Blood
(1994) - et al.
Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia
Blood
(1992) - et al.
Aggressive administration of recombinant oncotoxin AR209 (anti-ErbB-2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours
Eur J Cancer
(1998)
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
Blood
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study
Blood
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
Blood
Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion
Blood
Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome
Exp Cell Res
Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells
J Biol Chem
Targeting Pseudomonas exotoxin to hematologic malignancies
Semin Cancer Biol
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin’s lymphoma
Blood
Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity
Blood
Vascular leak syndrome: a side effect of immunotherapy
Immunopharmacology
An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers
Blood
Diphtheria toxin and related proteins I. Isolation and properties of mutant proteins serologically related to diphtheria toxin
J Biol Chem
Localization of the diphtheria toxin receptor-binding domain to the carboxyl-terminal Mr ∼ 6000 region of the toxin
J Biol Chem
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli
Cell
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol
J Biol Chem
Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol
J Biol Chem
The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes
J Biol Chem
Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin
J Biol Chem
Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver
J Biol Chem
Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194
J Biol Chem
An intact transmembrane helix 9 is essential for the efficient delivery of the diphtheria toxin catalytic domain to the cytosol of target cells
J Biol Chem
Comparison of ribosome-inactivating proteins in the induction of apoptosis
Toxicol Lett
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation
Blood
Cancer statistics, 1998
CA Cancer J Clin
Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin
Nat Med
Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin
Bioconjug Chem
Using cytokine receptors to target leukemia and lymphoma with fusion toxins
Methods in Molecular Medicine: Drug Targeting
BIACORE: an affinity biosensor system for characterization of biomolecular interactions
Biochem Soc Trans
Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia
Cancer Res
The recombinant immunotoxin anti-Tac(Fv)-Pseuodomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia
Proc Natl Acad Sci USA
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice
Int J Cancer
Antitumor activity of Fab’ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites
Cancer Res
In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin
Clin Cancer Res
Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma
Cancer Res
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin
Ann Intern Med
CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy
Leuk Lymphoma
Phase I trial of an Anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin’s lymphoma: effect of an intensive schedule of administration
J Immunother
Anti-B4-blocked ricin: a Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms
J Clin Oncol
Cited by (192)
A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses
2023, European Journal of PharmacologyRecent advances in microbial toxin-related strategies to combat cancer
2022, Seminars in Cancer BiologyCitation Excerpt :Cancer immunotherapy hijacks the host’s immune systems and allows various immune cells such as tumor antigen‐specific CD8+ and CD4+ T lymphocytes to identify and attack cancer cells leading to cell death [41]. Immunotoxins get attached through binding ligands that fuse with target moiety via surface antigens, helps in internalization and killing the cells through catalytic protein synthesis inhibition inside the cell cytosol [45,46]. Another approach includes expression-targeting where the cytolethal agent's gene is transmitted to cells and limits its expression through transcriptional regulation in cancer cells.
Critical Issues in the Development of Immunotoxins for Anticancer Therapy
2020, Journal of Pharmaceutical SciencesGlycan-targeted PEGylation for selective modification of proteins
2019, Polymer-Protein Conjugates: From Pegylation and BeyondToxins as tools
2015, The Comprehensive Sourcebook of Bacterial Protein ToxinsEngineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges
2021, Advanced Materials